The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial.
 
Dingwei Ye
No Relationships to Disclose
 
Bo Dai
No Relationships to Disclose
 
Weijie Gu
No Relationships to Disclose
 
Shusuan Jiang
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Fang-Jian Zhou
No Relationships to Disclose
 
Dalin He
No Relationships to Disclose
 
Lulin Ma
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Chaochao Liang
No Relationships to Disclose
 
Tie Chong
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Zhiwen Chen
No Relationships to Disclose
 
Yong Wang
No Relationships to Disclose
 
Qing Zou
No Relationships to Disclose
 
Ye Tian
No Relationships to Disclose
 
Jun Xiao
No Relationships to Disclose
 
Xinfeng Yang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Jianpo Lian
Employment - Jiangsu Hengrui Pharmaceuticals
 
Wenliang Wang
Employment - Jiangsu Hengrui Pharmaceuticals